TMT-Based Quantitative Proteomics in Cancer Research
Cancer is a highly heterogeneous and complex disease, involving biological processes at multiple levels, including gene mutations, regulation of protein expression, and dysregulation of signaling pathways. Although high-throughput transcriptomic techniques such as RNA-Seq have been extensively applied in cancer research, transcriptional profiles do not fully reflect protein expression or functional states. TMT-based quantitative proteomics, a relative quantification approach utilizing isobaric mass tags, allows high-throughput, accurate comparison of protein expression across multiple samples and has become an essential tool in cancer research.
Technical Advantages of TMT in Cancer Research
1. Simultaneous quantification across multiple sample groups: Suitable for comparisons such as cancer tissue versus normal tissue, different tumor stages, or pre- and post-drug intervention.
2. High sensitivity and proteome coverage: Capable of detecting low-abundance cancer-associated proteins.
3. High reproducibility: Facilitates biomarker discovery and validation.
4. Supports post-translational modification (PTM) studies: Enables analysis of phosphorylation, acetylation, and other PTMs to investigate signaling pathway activation states.
Commonly used TMT reagents include TMT 6plex, 10plex, 11plex, 16plex, and TMTpro 18plex, enabling parallel analysis of up to 18 samples in a single experiment.
Application Scenarios of TMT in Cancer Research
1. Cancer Biomarker Discovery and Validation
TMT allows comparison of protein expression profiles between tumor tissues and adjacent normal tissues, facilitating the identification of potential early diagnostic markers, prognosis-associated proteins, or secreted proteins detectable in serum.
2. Tumor Subtype Characterization
Many cancer types, such as breast, gastric, and lung cancers, exhibit distinct molecular subtypes. TMT can help identify subtype-specific protein expression patterns, reveal functional pathway differences, and guide personalized therapeutic strategies.
3. Mechanistic Studies of Anticancer Drugs
TMT-based quantitative proteomics can evaluate changes in protein expression before and after drug treatment, identifying drug targets and affected pathways, thereby supporting mechanistic studies and assessment of potential side effects.
4. Cancer Microenvironment and Immune Response Studies
Through TMT proteomic analysis of tumor-infiltrating immune cells, stromal cells, and exosomes, researchers can investigate the effects of the tumor microenvironment (TME) on tumor progression, metastasis, and immune evasion.
(1) Analyze tumor-infiltrating T cell proteomes to identify markers of immune exhaustion.
(2) Analyze tumor-derived exosomes to discover molecules associated with metastasis.
(3) Combine with phosphoproteomics to assess activation states of immune signaling pathways.
Challenges and Strategies of TMT in Cancer Research
MtoZ Biolabs has accumulated extensive expertise in sample preparation, differential protein screening, and immune-related pathway analysis in cancer research, ensuring both data quality and biological interpretability.
Technical Capabilities of MtoZ Biolabs TMT Quantitative Proteomics Services
To meet the diverse requirements of cancer research, MtoZ Biolabs provides comprehensive technical support for TMT-based proteomics:
1. Supports multiple TMT multiplexing formats (6plex-18plex), adaptable to different experimental scales.
2. Based on high-resolution platforms such as Orbitrap Fusion Lumos, supporting both MS2 and SPS-MS3 acquisition modes to ensure high-accuracy quantification.
3. One-stop bioinformatics analysis pipeline, including differential protein analysis, pathway enrichment, PPI network construction, and tumor subtype prediction.
4. Integrated TMT + PTM analysis capabilities, supporting studies of phosphorylation, ubiquitination, and other post-translational modifications.
5. Scalable multi-omics integration, including combined proteomics, metabolomics, and transcriptomics study designs.
If you are conducting cancer proteomics research, MtoZ Biolabs can provide customized experimental design and technical support based on your research objectives, sample characteristics, and budget requirements. TMT-based quantitative proteomics not only enables precise profiling of protein expression levels, but also accelerates cancer mechanism discovery and biomarker validation through its multiplexed high-throughput capability. Through collaboration with MtoZ Biolabs, researchers can facilitate the generation of reliable scientific findings and potential clinical applications by fully leveraging the advantages of TMT technology.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
